Privia Health Group, Inc. files SEC reports that document its physician enablement business, operating results, governance and public-company capital structure. Its 8-K reports commonly furnish quarterly and annual financial releases, including revenue, care margin, platform contribution, adjusted EBITDA, guidance, value-based risk arrangements and provider-network growth.
Proxy and other material-event filings cover board and committee governance, shareholder voting matters, material agreements, risk factors, regulatory disclosures and other updates tied to a Delaware corporation listed on Nasdaq under PRVA.
Privia Health Group’s executive vice president and chief financial officer reported an insider transaction involving stock option exercises and a related share sale on 12/12/2025. She exercised stock options at an exercise price of $2 per share, acquiring 23,887 shares of common stock, and then sold 23,887 shares of common stock at a weighted average price of $25.03 per share under a previously adopted Rule 10b5-1 trading plan.
After these transactions, she beneficially owned 172,909 shares of common stock directly and 8,695 shares indirectly through her spouse. She also continued to hold fully vested and exercisable stock options with remaining positions including 17,820, 12,452, 5,501 and 2,866 options, each relating to common stock at a $2 exercise price, with expiration dates ranging from 08/27/2028 to 09/07/2030.
Privia Health Group (PRVA) reported Q3 results highlighting strong growth and solid liquidity. Revenue reached $580.4 million, up from $437.9 million, with operating income of $14.4 million versus $5.8 million. Net income attributable to Privia was $6.9 million ($0.05 diluted EPS), compared with $3.5 million a year ago. Value-based care momentum continued as shared savings benefited from a $23.8 million change in estimate tied to the 2024 MSSP performance.
Cash and cash equivalents were $441.4 million, and no amounts were drawn on the $125 million revolving credit facility. Accounts receivable rose to $499.0 million, reflecting higher volumes and VBC accruals, while provider liability increased to $495.7 million. The company closed the PMG-AZ acquisition, adding $64.4 million of payer/physician network intangibles and $30.6 million of goodwill; PMG-AZ contributed $37.0 million of revenue post-close.
After quarter-end, Privia received $156.9 million from CMS for 2024 MSSP shared savings, of which $88.4 million will be disbursed to providers, and signed a definitive agreement to acquire an ACO business from Evolent Health for $100.0 million in cash plus up to $13.0 million, subject to customary conditions.
Privia Health Group, Inc. furnished an 8-K announcing its financial results for the third quarter ended September 30, 2025. The company issued a press release on November 6, 2025, attached as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is stated as “furnished” and not “filed” under the Exchange Act. Privia Health’s common stock trades on the Nasdaq Global Select Market under the symbol PRVA.
Privia Health Group, Inc. (PRVA) reported the passing of Board member Patricia Maryland on October 24, 2025. She served on the Board for five years and was Chair of the Compliance Committee. The company expressed gratitude for her service and contributions.
The report is filed under Item 8.01 (Other Events) and was signed by Chief Executive Officer Parth Mehrotra. No additional board or committee actions are described in this disclosure.
Privia Health Group, Inc. (PRVA) filed a Current Report describing material risks and uncertainties affecting its business. The filing highlights regulatory and compliance exposure in a heavily regulated healthcare environment, the complexity of relationships with medical groups and Privia providers, and execution risks for its growth strategy and proprietary cloud-based technology rollout. It notes reliance on key vendors such as athenahealth, Inc., potential reimbursement rate pressure from government and private payers, cybersecurity and privacy risks related to protected health information, and workforce availability and cost pressures. The report references risk disclosures through year ended December 31, 2024 and states information is current as of the report date.
Privia Health Group, Inc. (PRVA) filed a Current Report describing material risks and uncertainties affecting its business. The filing highlights regulatory and compliance exposure in a heavily regulated healthcare environment, the complexity of relationships with medical groups and Privia providers, and execution risks for its growth strategy and proprietary cloud-based technology rollout. It notes reliance on key vendors such as athenahealth, Inc., potential reimbursement rate pressure from government and private payers, cybersecurity and privacy risks related to protected health information, and workforce availability and cost pressures. The report references risk disclosures through year ended December 31, 2024 and states information is current as of the report date.
Privia Health Group, Inc. Schedule 13G discloses that a Rubicon-linked group holds a material passive stake in the company's common stock. The Reporting Persons beneficially own 6,278,522 shares, representing 5.14% of the outstanding class based on the issuer's reported total of 122,673,254 shares. All voting and dispositive power over these shares is reported as shared (no sole voting or dispositive power). The shares are held through Puma Growth Holdings, LLC, with a clear chain of control: Puma owns the shares, RF OP GP acts as manager, RF OP GP 2 is the general partner of RF OP GP, and Rubicon Founders is the ultimate member; Adam Boehler is identified among the Reporting Persons. The filing is submitted on Schedule 13G and includes a certification that the stake is not held to influence control of the issuer.
Privia Health Group (PRVA) posted solid top-line growth in Q2 2025. Revenue rose 23.4 % to $521.2 million, driven by stronger Value-Based Care (capitated +34 % to $75.5 million; shared-savings +51 % to $60.0 million) and fee-for-service patient care of $331.5 million. Six-month revenue reached $1.00 billion, up 19.5 % year-over-year. Gross profit improved 14.8 % to $112.8 million.
Earnings moderated. Operating income fell to $3.3 million (-34.6 %), and net income attributable to PRVA slipped to $2.7 million (EPS basic $0.02 vs. $0.03). YTD net income rose 7.1 % to $6.9 million on better first-quarter results.
Cash deployment and balance sheet. The company closed a 51 % acquisition of Privia Medical Group Arizona for $89.1 million cash, lifting goodwill to $172.2 million and intangibles to $170.1 million. Cash & equivalents declined to $390.1 million from $491.1 million at year-end, reflecting the deal and a $16.1 million operating cash outflow. No borrowings are outstanding on the $125 million revolver; total debt remains zero. Stockholders’ equity increased to $733.5 million on share issuance and retained earnings.
Key operating metrics. Implemented providers grew 13.8 % to 5,125, and attributed lives rose 15.2 % to 1.38 million. Practice collections reached $862.9 million (+18.5 %). Provider liability climbed to $458.1 million, and accounts receivable to $444.0 million.
Management continues to highlight expansion into 16 markets, including recent entries into Indiana and Arizona, and underscores the shift toward higher-margin VBC contracts while maintaining a strong liquidity position.